DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Zarontin (Ethosuximide) - Indications and Dosage

 
 



INDICATIONS AND USAGE

Zarontin is indicated for the control of absence (petit mal) epilepsy.

DOSAGE AND ADMINISTRATION

Zarontin is administered by the oral route. The initial dose for patients 3 to 6 years of age is one capsule (250 mg) per day; for patients 6 years of age and older, 2 capsules (500 mg) per day. The dose thereafter must be individualized according to the patient's response. Dosage should be increased by small increments. One useful method is to increase the daily dose by 250 mg every four to seven days until control is achieved with minimal side effects. Dosages exceeding 1.5 g daily, in divided doses, should be administered only under the strictest supervision of the physician. The optimal dose for most pediatric patients is 20 mg/kg/day. This dose has given average plasma levels within the accepted therapeutic range of 40 to 100 mcg/mL. Subsequent dose schedules can be based on effectiveness and plasma level determinations.

Zarontin may be administered in combination with other anticonvulsants when other forms of epilepsy coexist with absence (petit mal). The optimal dose for most pediatric patients is 20mg/kg/day.

HOW SUPPLIED

Zarontin is supplied as:

N 0071-0237-24—Bottles of 100. Each capsule contains 250 mg ethosuximide.

Store at 25 ° C (77 ° F); excursions permitted to 15—30 ° C (59—86 ° F) [see USP Controlled Room Temperature].

Rx only

LAB-0094-5.0

April 2009

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012